Systemic treatments for women with breast cancer: outcome with relation to screening for the disease

Goldhirsch, Aron; Colleoni, Marco; Domenighetti, G.; Gelber, Richard D.

doi:10.1093/annonc/mdg327

Cited by 27 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While protein bound paclitaxel can be administered more quickly and is considered water-soluble [15,53], the underlying problems with side effects and damage to normal, healthy cells and tissues still remains. As such, treatment effectiveness is still based not only on cancer stage at diagnosis, but also patient responsiveness and the overall health of the patient [41,[54][55][56].…”

Section: Discussionmentioning

confidence: 99%

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Gollahon¹

2011

TOBCANJ

View full text Add to dashboard Cite

Abstract:With the exception of a few anticancer agents, most breast cancer chemotherapeutics currently used have devastating effects on normal cells. We investigated the effectiveness of the natural product NI-07, derived from Arctium lappa, to determine its killing potential on breast cancer cells and its cytotoxic effects in breast normal cells. The breast cancer cell lines HCC1419, MCF7, MDA-MB-231, MDA-MB-468, SKBR3, the normal mammary epithelial cell line HME 50 HT and the normal mammary fibroblast cell line CCD-1074sk were analyzed in concurrently treated cultures of NI-07, Taxol™ or Untreated. NI-07-treated and Taxol™ -treated cells were cultured for two weeks to assess cell resistance/recovery. Cell viability was determined by cell counts, Trypan Blue exclusion and microscopy. Additionally, cell viability and cytotoxicity were measured by XTT. Statistical significance (p 0.05) of NI-07 to Untreated or Taxol™ was first determined using Two-Way ANOVA. Identified significant differences were further analyzed by One-Way ANOVA and Tukey's test for honestly significant differences. The effect size of NI-07 compared to untreated or Taxol™ was determined using Cohen's d. Our results showed significant declines in cell viability occurring in NI-07-treated cancer cells after 48 hours of treatment in contrast to the more rapid effect of Taxol™ (<24h). Additionally, cancer cell recovery was less effective in NI-07 versus Taxol™. Furthermore, NI-07 showed no cytotoxicity in normal cells. This lack of cytotoxicity, coupled with its killing efficiency in cancer cells, suggests that NI-07 could potentially make a strong anti-cancer compound or neo-adjuvant to current chemotherapy-based treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Gollahon¹

2011

TOBCANJ

View full text Add to dashboard Cite

show abstract

“…Although early detection of cancer has improved survival for a number of cancers, including breast cancer [29], colon cancer [30–32], prostate cancer [33, 34], and cervical cancer [35], existing serum biomarkers for breast cancer are not adequate for early detection. The possibility of early detection of breast cancer may be realized through both noninvasive (i.e., imaging technologies) and invasive means (patient serum profiling).…”

Section: Introductionmentioning

confidence: 99%

Protein Biomarkers for the Early Detection of Breast Cancer

Misek

Kim

2011

International Journal of Proteomics

View full text Add to dashboard Cite

Advances in breast cancer control will be greatly aided by early detection so as to diagnose and treat breast cancer in its preinvasive state prior to metastasis. For breast cancer, the second leading cause of cancer-related death among women in the United States, early detection does allow for increased treatment options, including surgical resection, with a corresponding better patient response. Unfortunately, however, many patients' tumors are diagnosed following metastasis, thus making it more difficult to successfully treat the malignancy. There are, at present, no existing validated plasma/serum biomarkers for breast cancer. Only a few biomarkers (such as HER-2/neu, estrogen receptor, and progesterone receptor) have utility for diagnosis and prognosis. Thus, there is a great need for new biomarkers for breast cancer. This paper will focus on the identification of new serum protein biomarkers with utility for the early detection of breast cancer.

show abstract

“…Early detection of cancer has improved survival for several cancers, including breast, 11 colon, [12][13][14] prostate, 15,16 and cervical cancers. 17 Early detection of PDAC may be possible through both noninvasive (i.e., imaging technologies) and invasive means (analysis of pancreatic juice and patient serum profiling).…”

mentioning

confidence: 99%

Early Detection and Biomarkers in Pancreatic Cancer

Misek

Patwa

Lubman

et al. 2007

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Major advances in cancer control will be greatly aided by early detection for diagnosing and treating cancer in its preinvasive state before metastasis. Unfortunately, for pancreatic ductal adenocarcinoma (PDAC), which is the fourth leading cause of cancer-related death in the United States, effective early detection and screening are currently not available and tumors are typically diagnosed at a late stage, frequently after metastasis. Partly because of low sensitivity/specificity, existing biomarkers such as CA19-9 are not adequate as early detection markers of pancreatic cancer. Thus, a great need exists for new biomarkers for pancreatic cancer. This article focuses on recent developments in the identification of new serum protein biomarkers that are useful in the early detection of PDAC.

show abstract

Systemic treatments for women with breast cancer: outcome with relation to screening for the disease

Cited by 27 publications

References 15 publications

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Protein Biomarkers for the Early Detection of Breast Cancer

Early Detection and Biomarkers in Pancreatic Cancer

Contact Info

Product

Resources

About